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We investigated the conservation and antibody accessibility of inner core epitopes of Neisseria meningitidis
lipopolysaccharide (LPS) because of their potential as vaccine candidates. An immunoglobulin G3 murine
monoclonal antibody (MAb), designated MAb B5, was obtained by immunizing mice with a galE mutant of N.
meningitidis H44/76 (B.15.P1.7,16 immunotype L3). We have shown that MAb B5 can bind to the core LPS of
wild-type encapsulated MC58 (B.15.P1.7,16 immunotype L3) organisms in vitro and ex vivo. An inner core
structure recognized by MAb B5 is conserved and accessible in 26 of 34 (76%) of group B and 78 of 112 (70%)
of groups A, C, W, X, Y, and Z strains. N. meningitidis strains which possess this epitope are immunotypes in
which phosphoethanolamine (PEtn) is linked to the 3-position of the b-chain heptose (HepII) of the inner core.
In contrast, N. meningitidis strains lacking reactivity with MAb B5 have an alternative core structure in which
PEtn is linked to an exocyclic position (i.e., position 6 or 7) of HepII (immunotypes L2, L4, and L6) or is absent
(immunotype L5). We conclude that MAb B5 defines one or more of the major inner core glycoforms of N.
meningitidis LPS. These findings support the possibility that immunogens capable of eliciting functional
antibodies specific to inner core structures could be the basis of a vaccine against invasive infections caused
by N. meningitidis.
Septicemia and meningitis caused by Neisseria meningitidis
remain a global health problem, especially in young children.
N. meningitidis is usually a commensal of the nasopharynx, the
only major natural reservoir of this organism. The virulence
factors that potentiate the capacity of N. meningitidis to cause
invasive disease include capsular polysaccharides, pili (fimbri-
ae) or outer membrane proteins and lipopolysaccharides
(LPS) (12, 23, 39, 45, 48, 63, 68). Existing licensed vaccines
against capsular serogroups A, C, W, and X are available (15,
20, 51) but generally lack satisfactory immunogenicity in very
young children and do not induce long-lasting protective im-
munity (8, 33, 42, 43, 49). Nonetheless, their utility has been
significant in affording protection to selected populations such
as the military, travellers, and those at exceptional risk in
outbreaks or epidemics (10). The problems are to identify
vaccines that are highly effective in infants and to give long-
term protection against group B strains. Group B strains have
accounted for a substantial, often a majority of invasive N.
meningitidis infections in many countries in Europe and the
United States (11). Prevention of group B invasive disease
represents a particularly difficult challenge in vaccine develop-
ment since the capsular polysaccharide is very poorly immu-
nogenic and even conjugates have shown disappointing immu-
nogenicity (24). Further, there are concerns about the safety of
vaccines whose rationale is to induce antibodies to the group B
polysaccharide, a homopolymer of a-linked 2-8 neuraminic
acid. The identical polysialic acid is a posttranslational modi-
fication of a glycoprotein present on human cells, especially
neurons, and is referred to as neural cell adhesion molecule
(14). Both theoretical and experimental evidence have been
used to argue that the induction of antibodies might result in
autoimmune, pathological damage to host tissues. Alternative
approaches for developing vaccine candidates against group B
N. meningitidis are being actively explored. These include:
outer membrane porins (47, 50, 75, 76), transferrin-binding
proteins (2), and LPS (19, 25, 27, 38, 69).
The structure of N. meningitidis LPS has been studied in
considerable detail by Jennings and coworkers with additional
contributions by others (4, 18, 44, 59, 64). The structures of
major glycoforms for several immunotypes (L1 to L9) have
been published: L1 and L6 (13, 73), L3 (41), L5 (37), L2 (16),
L4 and L7 (32), and L9 (26) (Fig. 1). It is known that, in
addition to this interstrain variation, individual N. meningitidis
strains exhibit extensive phase variation of outer core LPS
structures (reviewed in references 3 and 66). The molecular
mechanism of this intrastrain variation involves hypermutable
loci within the reading frames of several glycosyl transferases
(17, 28). Similar mechanisms of phenotypic variation have
been reported for other phase-variable surface components of
pathogenic Neisseria spp., including Opc (52), Opa (61), and
PilC proteins (31). This high-frequency, reversible molecular
switching of LPS is mediated by homopolymeric tracts of cy-
tosines or guanines through slippage-like mechanisms that re-
sult in frameshifts (17, 28, 60). Despite the extensive antigenic
variation of LPS, the inner core of the LPS is relatively highly
conserved. Furthermore, key biosynthetic genes for each step
have been identified (reviewed in reference 48), and this allows
* Corresponding author. Mailing address: Department of Clinical
Immunology, Churchill Hospital, Oxford OX3 7LJ, United Kingdom.
Phone: (01865)-226002. Fax: (01865)-225990. E-mail: Joyce.Plested
@paediatrics.ox.ac.uk.
5417
 o
n
 O
ctober 13, 2015 by University of Queensland Library
http://iai.asm
.org/
D
ow
nloaded from
 
the construction of a series of mutants from which LPS glyco-
forms of various sizes and complexities can be made available
to facilitate the identification of conserved epitopes (29, 30, 64,
65). Our hypothesis is that one or more of these inner core
epitopes may be conserved and accessible to antibodies and
that a specific immune response to these epitopes could me-
diate protection. If so, LPS inner core oligosaccharides could
be candidate vaccines.
Here we report that a monoclonal antibody (MAb), desig-
nated B5, has identified a cross-reacting epitope on the LPS of
the majority of naturally occurring but genetically diverse
strains of N. meningitidis. Critical to the epitope of strains
recognized by the MAb B5 is a phosphoethanolamine (PEtn)
on the 3-position of the b-chain heptose (HepII) (Fig. 1). In
contrast, all N. meningitidis strains lacking reactivity with MAb
B5 are immunotypes characterized by the absence of PEtn
substitution or by PEtn substitution at an exocyclic position
(i.e., position 6 or 7) of HepII (Fig. 1). Thus, a limited reper-
toire of inner core LPS variants is found among natural isolates
of N. meningitidis strains, and these findings support the pos-
sibility that a vaccine might be developed containing a few
glycoforms representative of all natural N. meningitidis strains.
MATERIALS AND METHODS
Bacterial strains. The N. meningitidis strains MC58 and H44/76 (both B:15:
P1.7,16 immunotype L3) have been described previously (21, 71). Derivatives of
MC58 and H44/76 with defined alterations in LPS were obtained by inactivating
the genes, galE (30), lsi (29), lgtA and lgtB (28), rfaC (62), and icsA and icsB (64)
(Table 1). Other wild-type N. meningitidis strains used in the study were from
three collections: (i) representatives of immunotypes L1 to L12 (46), a (ii) global
collection of 34 representative N. meningitidis group B strains (56), and (iii) a
global collection of 100 strains from 107 representative N. meningitidis strains of
all major serogroups (A, B, C, W, X, Y, and Z) (35).
Capsule-deficient and galE mutants were constructed in six N. meningitidis
group B strains obtained from the collection described earlier (56) (Table 1).
Other, related Neisseria strains studied included 10 strains of N. gonorrhoeae and
the commensal strains N. lactamica (eight strains), N. polysaccharea (one strain),
N. mucosa (one strain), N. cinerea (one strain), N. elongata (one strain), N. sicca
(one strain), and N. subflava (one strain). Other gram-negative organisms in-
cluded: Haemophilus influenzae type b (seven strains), H. somnus (one strain),
nontypable H. influenzae (eight strains), Escherichia coli (one strain), and Sal-
monella typhimurium (one strain) and its isogenic LPS mutants (rfaC, rfaP, and
rfaI) (Table 1).
Bacterial culture in vitro. All strains were grown overnight at 37°C on standard
brain heart infusion (BHI) medium base (Oxoid) in an atmosphere of 5% CO2.
Bacterial culture in vivo using the chick embryo model. To determine the
accessibility of inner core epitopes of N. meningitidis grown in vivo, the chick
embryo model was used (6, 7, 55). The method was modified by using an
inoculum of 104 or 105 N. meningitidis organisms in a final volume of 0.1 ml to
infect the chorio-allantoic fluid of 10-day-old Pure Sussex chick eggs (obtained
from the Poultry Unit, Institute of Animal Health, Compton, Berkshire, United
Kingdom). After overnight incubation (37°C), the allantoic fluid (ca. 3 to 5 ml)
was removed from the eggs, and the bacteria were recovered after centrifugation
at 350 3 g for 15 min. The organisms were washed in sterile phosphate-buffered
saline (PBS) and stored in Greaves solution (5% bovine serum albumin [BSA],
5% sodium glutamate, 10% glycerol) at 270°C.
LPS extraction. LPS samples were obtained from an overnight growth of N.
meningitidis plated on five BHI plates from which the organisms were scraped
and suspended in 30 ml of 0.05% phenol in PBS and incubated at room tem-
perature for 30 min. Alternatively, batch cultures were prepared in fermenters
with bacteria from an overnight growth (six plates) in 50 ml of Bacto Todd-
Hewitt broth (Difco) to inoculate 2.5 liters of the same medium. For insertion
mutant strains, the medium contained 50 mg of kanamycin per ml. After incu-
bation at 37°C for 6 to 8 h, the culture was inoculated into 60 liters of Bacto
Todd-Hewitt broth in a New Brunswick Scientific 1F-75 fermenter. After over-
night growth (17 h at 37°C), the culture was killed by the addition of phenol (1%)
and then chilled to 15°C; the bacteria were then harvested by centrifugation
(13,000 3 g for 20 min) (72). In either case, the crude LPS was extracted from
the bacterial pellet by using the standard hot phenol-water method (74) and
purified from the aqueous phase by repeated ultracentrifugation (105,000 3 g,
4°C, two times for 5 h) (36).
Tricine gels. Equivalent amounts of whole-cell (WC) lysates of N. meningitidis
strains or purified LPS were boiled in dissociation buffer and separated on
standard tricine gels (30 mA for 18 h) (34). Gels were fixed and silver stained
according to the manufacturer’s instructions (Bio-Rad). To determine the pres-
ence of sialic acid, WC lysates were incubated with 2.5 ml of neuraminidase at
37°C for 18 to 20 h (4 U/ml; Boehringer 1585886) and then with 5 ml of
proteinase K at 60°C for 2 to 3 h to remove proteins (Boehringer 1373196) prior
to separation on tricine gels (16.5%).
Characterization of LPS from MAb B5-negative strains. LPS from wild-type
and galE, cap mutant MAb B5-negative strains were O deacylated with anhy-
drous hydrazine as described previously (5). O-Deacylated LPS were analyzed by
electrospray mass spectrometry (ES-MS) in the negative ion mode on a VG
Quattro (Fisons Instruments) or API 300 (Perkin-Elmer/Sciex) triple quadruple
mass spectrometer. Samples were dissolved in water which was diluted by 50%
with acetonitrile–water–methanol–1% ammonia (4:4:1:1), and the mixture was
enhanced by direct infusion at 4 ml/min. Deacylated and dephosphorylated LPS
(L8 odA HF) was prepared according to the following procedure. LPS (160 mg)
was treated with anhydrous hydrazine (15 ml) with stirring at 37°C for 30 min.
The reaction was cooled (0°C), cold acetone (270°C, 50 ml) was added gradually
to destroy excess hydrazine, and precipitated O-deacylated LPS (L8 odA) was
obtained by centrifugation. L8 odA was washed twice with cold acetone and then
redissolved in water and lyophilized. The structure of L8 odA was confirmed by
negative ion ES-MS before dephosphorylation. L8 odA was dephosphorylated by
treatment with 48% aqueous hydrogen fluoride (10 ml) at 0°C for 48 h. The
product was dialyzed against water, and the O-deacylated, dephosphorylated
LPS sample (L8 odA HF) was lyophilized (50 mg). Loss of phosphate was
confirmed by ES-MS.
Molecular modelling. Molecular modelling of LPS epitopes was carried out as
described previously (5). The starting geometry for all sugars was submitted to a
complete refinement of bond lengths, valence, and torsion angles by using the
molecular mechanics program MM3(92) (Quantum Chemistry Program Ex-
changer [QCPE], Indiana University, Bloomington, Ind.). All calculations were
performed by using the minimized coordinates for the methyl glycoside. The
phosphorus groups were generated from standard coordinates (Tripos Software;
Alchemy) and minimum energy conformations found in crystal structures. Cal-
culations were performed by the Metropolis Monte Carlo (MMC) method. All
pendant groups were treated as invariant except for the phosphorus groups,
which were allowed to rotate about the Cx-Ox and Ox-P bonds. The starting
FIG. 1. Representation of the structure of meningococcal LPS oligosaccha-
rides of immunotypes L1 to L9. Immunotypes are indicated to the extreme left.
The vertical line marks the junction between the inner core structures to the right
and outer core structures to the left. The epitope recognized by MAb B5 is
indicated in boldface (MAb B5 positive). Arabic numerals indicate the linkage
between sugars or amino sugars. Alpha and beta indicate the carbon 1 linkage at
the nonreducing end of the sugar. Genes for incorporating each of the key sugars
or amino sugars into the LPS oligosaccharide in the biosynthetic pathway are
indicated with arrows indicating where in the pathway the gene product is
required. Abbreviations: Kdo, 2-keto-2-deoxyoctulosonic acid; Gal, galactose:
GlcNAc, N-acetylglucosamine; Glu, glucose; Hep, heptose. Immunotype L5 has
no PEtn on the second heptose. The gene that adds the glucose to the second
heptose (lgtG) is phase variable.
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angles for the oligosaccharide were taken from the minimum energy conformers
calculated for each disaccharide unit present in the molecule. 24-Dimensional
MMC calculations of the hexasaccharides with or without PEtn groups attached
were carried out with 5,000 macro moves. The graphics were generated by using
the Schakal software (Egbert Keller, Kristal-lographisches Institut der Univer-
sita¨t, Freiburg, Germany).
Antibodies. (i) Rabbit polyclonal antibody. We used a rabbit polyclonal anti-
body specific for group B N. meningitidis capsular polysaccharide obtained by
immunizing a rabbit six times subcutaneously with lysates of MC58 at 2-week
intervals. The first and second immunizations contained Freund complete adju-
vant and Freund incomplete adjuvant, respectively. Serum was obtained from
bleed 6. To increase specificity for the group B capsular polysaccharide, rabbit
polyclonal antibody (1 ml) was incubated overnight at 4°C with ethanol-fixed
capsule-deficient MC58 (5 3 109 organisms/ml). This preadsorbed polyclonal
antibody did not react with a capsule-deficient mutant of MC58 as determined by
immunofluorescence microscopy.
(ii) MAbs to inner core LPS. Murine MAbs to H44/76 galE LPS were prepared
by standard methods. Briefly, 6- to 8-week-old BALB/c mice were immunized
three times intraperitoneally, followed by one intravenous injection with forma-
lin-killed galE mutant whole cells. Hybridomas were prepared by the fusion of
spleen cells with SP2/O-Ag 14 (57) as described earlier (9). Putative hybridomas
secreting galE-specific antibodies were selected by enzyme-linked immunosor-
bent assay (ELISA) employing purified LPS from L3 and its galE mutant and L2.
Immunoglobulin class, subclass, and light chain were determined by using an
isotyping kit (Amersham Canada Ltd., Oakville, Ontario, Canada). Clones were
expanded in BALB/c mice after treatment with pristane to generate ascitic fluid.
Spent culture supernatant was collected after in vitro culture of hybridoma cell
lines. Further testing of galE MAbs was carried out by screening against purified
LPS from N. meningitidis L3 lgtA, lgtB, and lgtE mutant strains (Fig. 1), and S.
typhimurium Ra and Re mutants. One of the MAbs, MAb B5 (immunoglobulin
G3 [IgG3]), was selected for more detailed study.
TABLE 1. Bacterial strains
Strain Relevant immunotypeand/or genotype
Source and/or
reference
Neisseria meningitidis
MC58 L3 CSF isolate (71)
H44/76 L3 21
MC58 galE 30
MC58 lsi1 (rfaF) 29
MC58 lgtA 28
MC58 lgtB 28
H44/76 rfaC 62
H44/76 icsA 64
H44/76 icsB 64
126E, 35E, H44/76, 89I, M981, M992, 6155, 892257, M978, 120M, 7880, 7889,
3200
L1 to L12, respectively 46
BZ157 L2 56
BZ157 galE This study
1000 NT 56
1000 galE This study
NGE30 NT 56
NGE30 galE This study
EG327 NT 56
EG327 galE This study
NGH38 L2 and L5 56
NGH38 galE This study
EG328 NT 56
EG328 galE This study
3906, NGH15, BZ133, BZ83, EG329, SWZ107, BZ198, NGH41, NG4/88, 2970,
BZ147, NGG40, NGH36, NG3/88, NGF26, NG6/88, NGH38, NGE28,
BZ169, 528, DK353, BZ232, DK24, BZ159, BZ10, BZ163, NGP20
56
B40, Z4024, Z4081, Z2491, Z3524, Z3906, Z5826, BZ10, BZ163, B6116/77, L93/
4286, NG3/88, NG6/88, NGF26, NGE31, DK24, 3906, EG328, EG327, 1000,
B534, A22, 71/94, 860060, NGG40, NGE28, NGH41, 890326, 860800, NG4/
88, E32, 44/76, 204/92, BZ8, SWZ107, NGH38, DK353, BZ232, E26, 400,
BZ198, 91/40, NGH15, NGE30, 50/94, 88/03415, NGH36, BZ147, 297-0
35
Neisseria lactamica L12, L13, L17, L18, L19, L20, and L22; N. polysaccharea P4;
N. mucosa M7; N. cinerea F1; N. elongata I8; N. sicca Q29; N. subflava U37
B. Spratt & N. Smith
Neisseria gonorrhoeae
F62, MS11, FA19, FA1090, 179008, 150002, 15253 R. Goldstein
SN-4 S. Normavk
P9-2 M. Virji
Haemophilus influenzae type b 22
Eagan, 7004, Rd, 5B33, 3Fe, E3Fi, E1B1 opsx rfaF orfH
PLAK33 lpxA 58
Haemophilus somnus 738 L1 J. Richards
Nontypeable Haemophilus influenzae 54, 375, 477, 1003, 1008, 1042, 1147, 1231 J. Eskola
Escherichia coli DH5a 40
Salmonella typhimurium LT2 rfaC rfaI rfaP 53
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(iii) Immunotyping MAbs. To determine the immunotypes of N. meningitidis
strains studied, especially L2 and L4 to L6, the following murine MAbs were used
in dot blots and whole-cell ELISA: MN42F12.32 (L2 and L5), MN4A8B2 (L3,
L7, and L9), MN4C1B (L4, L6, and L9), MN40G11.7 (L6), and MN3A8C (L5)
(54).
(iv) Huvec assay. Cultured human umbilical vein endothelial cells (Huvecs)
were prepared as described previously (70) and were infected with strains of N.
meningitidis for 3 h at 37°C. N. meningitidis strains were grown either in vitro or
in vivo by using the chick embryo model (as described above). The accessibility
of the inner core LPS epitopes of whole-cell N. meningitidis to specific MAb B5
was determined by using immunofluorescence and confocal microscopy. Gelatin-
coated glass coverslips coated with Huvecs were infected with wild-type N.
meningitidis as described previously (71), except that bacteria were fixed with
0.5% paraformaldehyde for 20 min instead of methanol. For accessibility studies,
coverslips were washed with PBS, blocked in 3% BSA-PBS, and incubated with
MAb B5 culture supernatant and/or preadsorbed polyclonal rabbit anticapsular
antibody. Binding of antibody to wild-type N. meningitidis strains was detected by
anti-mouse IgG rhodamine (tetramethyl rhodamine isocyanate [TRITC]; Dako)
and anti-rabbit IgG fluorescein isothiocyanate (FITC; Sigma). Huvecs were
stained with diaminophenylamine DAPI; (49,6-diamidino-2-phenylindole; 1 mg/
ml; Sigma). Mounted coverslips were viewed for immunofluorescence by using
appropriate filters (Zeiss microscope with Fluorograbber, Adobe Photoshop, or
confocal microscope [Nikon]).
ELISA. (i) Purified LPS ELISA. A solid-phase indirect ELISA with purified
LPS was used to determine the binding specificities of MAbs. Nunc Maxisorp
plates were coated overnight with 1.0 mg of purified LPS per well derived from
wild-type and mutants. LPS (10 mg/ml) was diluted in 0.05 M carbonate buffer
containing 0.02 M MgCl2 (pH 9.8). Nonspecific binding sites were blocked for 1 h
with 1% BSA-PBS (Sigma) and washed three times with PBS-Tween 20 (0.05%
[vol/vol]; PBS-T). Plates were incubated for 1 h with MAb B5 culture superna-
tant and washed three times in PBS-T. Primary antibody was detected with
anti-mouse IgG-alkaline phosphatase (Sigma and Cedarlane Laboratories, Ltd.)
incubated for 1 h, washed three times in PBS-T, and detected with p-nitrophenyl
phosphate alkaline phosphatase substrate system (Sigma and Kirkegaard &
Perry Laboratories). The reaction was stopped after 1 h with 50 ml of 3 M NaOH,
and the absorbance (A405–410) was determined (Dynatech EIA plate reader).
(ii) Inhibition ELISA. For inhibition ELISA studies, MAb B5 was incubated
with purified LPS samples prior to addition to L3 galE LPS-coated plates and
then assayed as described above.
(iii) WC ELISA. WC ELISA was performed by using heat-inactivated lysates
of N. meningitidis organisms as described previously (1). Nunc Maxisorp 96-well
plates were coated with 100 ml of bacterial suspension (optical density [OD] of
0.1 at A620) overnight at 37°C and blocked with 1% BSA-PBS; an identical
protocol was followed as for LPS ELISA.
Dot blots. Bacterial suspensions prepared as described above (2 ml) were
applied to a nitrocellulose filter (45 mm, pore size; Schleicher & Schuell) and
allowed to air dry. The same procedure as described for WC ELISA was followed
except that the detection substrate was 5-bromo-4-chloro-3-indolyl-phosphate–
nitroblue tetrazolium (2 mg/ml; Sigma). The color reaction was stopped after 30
min by several washes with PBS, and the blots were air dried.
RESULTS
To investigate the potential of inner core LPS structures of
N. meningitidis as vaccines, we have studied the reactivity of an
isotype IgG3 murine MAb, designated B5, raised against N.
meningitidis H44/76 immunotype L3 galE mutant. MAb B5 was
one of seven MAbs to the LPS inner core produced against N.
meningitidis immunotype L3 galE by standard immunological
methods (see Materials and Methods). Preliminary ELISA
testing showed that B5 cross-reacted with LPS from the L3
parent strain and with galE (lgtE), lgtA, and lgtB mutants but
did not cross-react with S. typhimurium Ra or Re LPS. In order
to determine the specific inner core epitope recognized by
MAb B5, various N. meningitidis strains of known structure
were examined by ELISA for cross-reactivity (Fig. 2). The
most significant finding of this analysis was that N. meningitidis
immunotype L4 LPS was not recognized by MAb B5. The only
structural difference between immunotypes L4 and L3 (which
is recognized by MAb B5) is the position of attachment of the
PEtn group (Fig. 3). In immunotype L3 LPS the PEtn is at-
tached at the 3-position of HepII, whereas in immunotype L4
LPS the PEtn is attached at the 6- or 7-position (Fig. 3).
Additionally, LPS from immunotype L2 and its galE mutant (in
which the PEtn group is attached at the 6-position and a
glucose residue is present at the 3-position of HepII) are not
recognized by MAb B5. Immunotype L5, which has no PEtn in
the inner core, is not recognized by B5, whereas immunotype
L8 and its galE mutant which have PEtn at the 3-position of
HepII are recognized. These results suggest that MAb B5
specifically recognises PEtn when it is attached at the 3-posi-
tion of HepII. In order to prove the essential inclusion of PEtn
in the epitope recognized by MAb B5, immunotype L8 odA
LPS was dephosphorylated (48% HF, 4°C, 48 h) (Fig. 3). The
absence of PEtn after dephosphorylation was confirmed by
ES-MS analysis. As indicated in Fig. 4, dephosphorylation of
L8 odA LPS abolished reactivity to MAb B5. To further char-
acterize the epitope recognized by MAb B5, several structur-
ally defined genetic mutants of immunotype L3 were screened
for cross-reactivity (Fig. 4). The highly truncated LPS of mu-
tant strain icsB was only weakly recognized, while mutant
strain icsA LPS was not recognized by MAb B5. These results
suggest that the presence of glucose on the proximal heptose
residue (HepI) is not absolutely necessary for binding by B5
but is required for optimal recognition (Fig. 1). Furthermore,
MAb B5 does not bind LPS in which both the glucose on the
b-chain and the N-acetylglucosamine residue on the b-chain
are absent. This suggests that the presence of N-acetylglu-
cosamine is required to present the PEtn residue in the correct
conformation for binding by MAb B5. Genetic modifications
that produce severely truncated LPS glycoforms were also ex-
amined for reactivity with MAb B5. LPS from immunotype L3
lsi which has a trisaccharide of Hep-Kdo-Kdo attached to lipid
A, as well as L3 PB4 which only contains the Kdo disaccharide
and lipid A, were not recognized by MAb B5 (Fig. 4). Inhibi-
tion ELISA studies (data not shown) were in accord with this
result, thus confirming the specificity of MAb B5 to the PEtn
molecule linked at the 3-position of HepII.
To demonstrate the ability of MAb B5 to recognize this
inner core epitope in encapsulated strains, we devised an assay
in which natural isolates of N. meningitidis were studied when
they were grown on and became adherent to tissue-cultured
cells (i.e., Huvecs). Initially, this methodology was developed
by using the fully encapsulated strain MC58. The advantages of
using the Huvec assay were that it provided a monolayer of
endothelial cells to which the bacteria could adhere and that it
provided a biologically relevant environment. Previous at-
tempts with N. meningitidis directly adherent to gelatin- or
FIG. 2. Cross-reactivity of MAb B5 with selected immunotypes and mutants
of N. meningitidis LPS and O-deacylated (odA) LPS as determined by solid-
phase ELISA. LPS glycoforms of immunotypes L2 (35E) (solid bars), L3 (H44/
76) (open bars), L4 (89I) (hatched bars), L5 (M981) (open bars), L8 (M978)
(horizontal-line-filled bars), wild-type, and respective mutants (galE, lgtA, or
lgtB), in a native or O-deacylated form, were coated onto ELISA plates (see
Materials and Methods), and the reactivity of MAb B5 was determined by
standard ELISA (OD, A410).
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matrigel-coated coverslips resulted in low numbers of adherent
bacteria after repeated washings and high levels of nonspecific
background staining.
Primary antibodies, MAb B5, and a polyclonal anticapsular
antibody were detected by use of anti-mouse TRITC and anti-
rabbit FITC, respectively. This demonstrated that an inner
core LPS epitope of the fully encapsulated strain (MC58) was
accessible to MAb B5 (Fig. 5a and b). Confocal microscopy
showed that MAb B5 and anticapsular antibodies colocalized
and that the result was consistent irrespective of the sequence
in which the antibodies were added. We also investigated, in
addition to this in vitro demonstration of accessibility of MAb
B5 to inner core LPS, organisms grown in vivo by using the
chick embryo model. Strain MC58 (104 organisms/ml) was
inoculated into chorioallantoic fluid of 10-day-old chick em-
bryos and harvested the next day to provide ex vivo organisms.
The results observed by confocal microscopy were identical to
those observed in vitro, that is, MAb B5 and anticapsular
antibodies colocalized (Fig. 5c and d). This demonstrated that
the inner core LPS epitopes were also accessible in vivo on
whole-encapsulated wild-type N. meningitidis.
The observation of double staining of the inner core LPS
epitope in the presence of capsule is key to the concept of this
approach, and therefore a number of controls were used to
confirm the validity of this finding. (i) The first control involved
double staining an MAb B5-negative strain (e.g., immunotype
L4 strain) with MAb B5 and anti-capsular antibody. This re-
sulted in no reactivity of MAb B5 by using a rhodamine filter
but positive reactivity with anticapsular antibody, ruling out a
band-passing effect during the recording of the pictures. (ii)
The second control involved single staining of encapsulated
MAb B5-positive strains with either MAb B5 alone or anticap-
sular antibody alone, followed by staining with rhodamine or
FIG. 3. Space-filling three-dimensional molecular models of the calculated (MMC) lowest-energy states of the core oligosaccharide from galE mutants of L3 (a),
L4 (b), and L8-dephosphorylated (c). The Kdo moiety indicated in gray is substituted at the O-5 position by the heptose disaccharide inner core unit (red); HepI
provides the point via a glucose residue (dark green) for extension to give a-chain epitopes, while HepII is substituted by an N-acetylglucosamine residue (lighter green)
at O-2. PEtn (brown) is shown in O-3 position in the L3 immunotype and O-6 in the L4 immunotype.
FIG. 4. Cross-reactivity of MAb B5 with genetically modified L3 LPS and
chemically modified L8 LPS from N. meningitidis, as determined by solid-phase
ELISA. LPS glycoforms of immunotype L8 (M978) (horizontal-line-filled bars)
chemically modified by O deacylation and HF treatment and immunotype L3
(H44/76) (open bars) galE, icsB, icsA, lsi, and PB4 mutants (O deacylated) were
coated onto ELISA plates (see Materials and Methods), and the reactivity of
MAb B5 was determined by standard ELISA (OD, A410).
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FITC, respectively. When the results were viewed at the ap-
propriate wavelength, there was no cross-reactivity seen during
immunofluorescent staining, nor any band-passing effect. (iii)
The third control involved double-staining an MAb B5-positive
or -negative strain with MAb B5 and anticapsular antibody.
This resulted in no capsular staining but either MAb B5-pos-
itive or -negative reactivity when viewed on the rhodamine
filter. This result excluded cross-reactivity during staining or
band-passing effect resulting in artifactual inner core staining.
To survey the extent of MAb B5 reactivity with other N.
meningitidis strains, three collections of strains were investi-
gated: (i) 12 strains representative of LPS immunotypes L1 to
L12; (ii) 34 group B strains selected to represent genetically
diverse isolates from many different countries obtained be-
tween the years 1940 and 1988 (56); and (iii) a global collection
of 107 genetically diverse strains representing all capsular se-
rogroups, also obtained from different countries from 1940 to
1994 (35).
Of the 12 immunotypes, MAb B5 recognized the LPS of
strains in which the inner core oligosaccharide has a PEtn
linked to the 3-position of HepII (Table 2 and Fig. 1). Thus,
immunotypes L2, L4, and L6 did not react with MAb B5,
whereas immunotypes L1, L3, and L7 to L12 were recognized
by MAb B5. This confirmed that the presence of PEtn in the
3-position of the HepII is necessary to confer MAb B5 reac-
tivity (Fig. 3).
To investigate further the MAb B5 reactivity with other
group B strains, a collection of genetically diverse strains was
studied (56). MAb B5 reactivity was detected in 26 of 34 (76%)
of group B N. meningitidis strains tested. This included repre-
sentative ET-5, ET-37, A4, and Lineage-3 strains. This repre-
sents the most complete available collection of hyperinvasive
lineages of N. meningitidis group B strains.
We obtained capsule-deficient and galE mutants from six of
eight of the MAb B5-negative group B strains (transformations
were unsuccessful in the other two strains). These strains were
FIG. 5. (a and b) Confocal immunofluorescence microscopy of in vitro-grown N. meningitidis MC58 adherent to Huvecs. (a) Fluorescein tagging with rabbit
polyclonal antibody specific for group B N. meningitidis capsule. (b) rhodamine tagging of MAb B5 specific for galE LPS. (c and d) Confocal immunofluorescence
microscopy of in vivo-grown MC58 organisms stained as described for panels a and b. (c) Anticapsular antibody (green). (d) MAb B5 (red). Magnification, 32,400 (all
four panels).
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also negative with MAb B5 as determined by dot blot, WC
ELISA, or immunofluorescence, with the exception of a
BZ157 galE capsule-deficient mutant, which had low-level re-
activity as seen both by immunofluorescence and by dot blot.
The MAb B5 strains were characterized by using a battery of
immunotyping MAbs. We determined the immunotype of the
eight MAb B5-negative strains by using combinations of the
appropriate MAbs (see Materials and Methods) and dot blots
of WC lysates (obtained from P. van der Ley) (Table 3). In
addition, structural fingerprinting of the inner core region of
MAb B5-negative strains was performed by ES-MS on O-
deacylated LPS from five of the respective capsule-deficient
galE mutants (1000, NGE30, EG327, BZ157, and NGH38)
(Table 4). Strains 1000, NGE30, and EG327 were nontypeable
as determined by the use of MAbs, and LPS from these strains
lacked PEtn on HepII of the inner core. BZ157, which corre-
sponded to immunotype L2 by MAbs, contained PEtn in the
inner core and, by analogy, to L2 at the 6/7-position of HepII
(Table 3). NGH38 was immunotype L2 and L5 and was anal-
ogous to L2 as determined by structural analysis. Those strains
that were nontypeable failed to react with MAbs that recognize
L3,7,9, L6, L2,5, and L4,6,9. However, 15 of 17 MAb B5-
negative N. meningitidis strains (all serogroups) were positive
for L2,5, and all MAb B5-positive strains were positive for
L3,7,9. No reaction with any immunotyping MAbs was ob-
served with 8 of 32 MAb B5-negative strains and 24 of 68 of
MAb B5-positive strains.
To determine if the degree of sialylation of the LPS was a
factor in the ability of MAb B5 to recognize its inner core
epitope, MAb B5-negative strains were examined by LPS gels.
MAb B5 reactivity was unaffected by varying the state of sia-
lylation through exposure to neuraminidase as described in
Materials and Methods (Fig. 6). Furthermore, strain MC58,
with which the MAb B5 reacted strongly, was found to be
highly sialylated (Fig. 6), and this finding was confirmed by
ES-MS of purified O-deacylated LPS (data not shown). There-
fore, our data did not support a contribution of sialylation to
the lack of MAb B5 reactivity.
With respect to the other Neisseria species, MAb B5 also
recognized the inner core LPS of five strains of N. gonorrhoeae
(F62, MS11, FA19, 179008, and 150002) (two were negative)
and (at least) two strains of N. lactamica (L19 and L22). How-
ever, MAb B5 did not react with one strain each of N. polysac-
charea (M7), N. mucosa (F1), N. cinerea (I8), N. elongata
(Q29), N. sicca (Q39), and N. subflava (U37). Also, MAb B5
did not react with E. coli (DH5 alpha) or S. typhimurium (LT2)
or its isogenic LPS mutants (rfaC, rfaI, and rfaP).
Finally, we investigated the reactivity of MAb B5 with 100
strains that included representatives of serogroups A, B, C, W,
X, Y, and Z (35). Of these strains, 70% were MAb B5 positive.
Clustering according to genetic relatedness was evident. For
example, none of the MAb B5-negative strains were in the ET5
complex. Among group A strains, MAb B5-positive and -neg-
ative strains also fell into distinct clusters. For example, lin-
eages I to III and lineage A4 were positive, and lineage IV to
VI was negative. This collection, together with the one de-
scribed earlier (56), represents the most complete set available
for known hyperinvasive lineages in all major serogroups of N.
meningitidis strains.
DISCUSSION
The prerequisites for any candidate N. meningitidis group B
vaccine would be that it contain a highly conserved epitope(s)
that is found in all group B strains and is accessible to anti-
bodies in the presence of capsule. Our approach has combined
genetics, structural analysis, and immunobiology to define can-
didate epitopes in inner core LPS of N. meningitidis group B.
This study used murine MAb B5, isotype IgG3, which was
TABLE 2. Reactivity of MAb B5 with representative N. meningitidis strains of immunotypes L1 to L12 as determined by WC ELISA, dot
blots of lysates, immunofluorescence, and confocal microscopy
Strain Serogroup: serotype Immunotype WC ELISA(OD, A405)a
Dot blotb Immuno-fluorescencec
126E C:3:P1.5,2 L1 11.8 111 1
35E C:20:P1.1 L2 2,0.4 2 2
H44/76 B:15.P1.7,16 L3 11.3 111 11
89I C:nt:P1.16 L4 2,0.4 2 2
M98I B:4:P1.2 L5 2,0.4 6 2
M992 B:5:P1.7,1 L6 2,0.4 6 2
6155 B:nt:P1.7,1 L7 10.8 11 1
M978 B:8:P1.7,1 L8 11.9 111 11
892257 B:4:P1.4 L8 11.9
120M A:4:P1.10 L9 11.8 111 1
7880 A:4:P1.6 L10 12.2 111 1
7889 A:4:P1.9 L11 12.0 111 11
3200 A:4:P1.9 L12 12.1 111 11
a 1, positive reactivity (OD . 0.4); 2, negative reactivity (OD , 0.4).
b 111, strongly positive; 11, positive; 6, weakly positive; 2, negative.
c 11, strongly positive; 1, positive; 2, negative.
TABLE 3. Correlation between reactivity with MAb B5,
immunotyping, and location of PEtn on HepII of the inner core
Strain MAb B5 Immunotypea
Position of PEtn
on HepII
O-3 O-6
MC58 1 L3 and L7 1 2
1000 2 NT 2 2
NGE30 2 NT 2 2
EG327 2 NT 2 2
BZ157b 2 L2 and L5 2 1
BZ157c 1 L3 and L7 1 2
NGH38 2 L2 and L5 2 1
a NT, nontypeable. MN4A8B2 (L3, 7, 9), MN42F12.32 (L2,5), MN4C1B
(L4,6,9), and MN40G11.7 (L6).
b BZ157, MAb B5-negative variant.
c BZ157, MAb B5-positive variant.
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raised to a genetically defined immunotype L3 galE mutant in
order to specifically target inner core LPS epitopes. The
epitope(s) recognized by MAb B5 was defined by cross-reac-
tivity studies with purified LPS glycoforms of known structure.
MAb B5 recognized all LPS glycoforms in which the PEtn is at
the 3-position of HepII (immunotypes L1, L3, L7, L8, and L9)
and failed to react with immunotypes where PEtn is at the 6-
or 7-position (L2, L4, and L6) or absent from HepII (L5) (Fig.
1). MAb B5 reacted with 70% of the N. meningitidis strains
tested from the two most complete sets of N. meningitidis
strains available worldwide (35, 56). Of these strains, 76% of
the N. meningitidis group B strains tested were positive with
MAb B5, and 70% of a collection that included all N. menin-
gitidis serogroups tested were positive with MAb B5. There-
fore, it may be envisaged that a vaccine containing a limited
number of glycoforms, representing all the possible PEtn po-
sitions (none, 3, and 6/7) on HepII of the inner core, would
cover 100% of N. meningitidis group B strains.
The LPS structures of MAb B5-negative strains were con-
firmed by structural analysis. Two structural variants were rec-
ognized: one variant without PEtn in the inner core LPS (e.g.,
NGE30, EG327, and 1000) and the other with PEtn group on
HepII (e.g., BZ157 and NGH38) at the 6- or 7-position instead
of the 3-position.
With a view to developing inner core LPS epitopes as vac-
cine candidates, it is significant that there were no effects of the
capsule on MAb B5 accessibility, as shown by colocalization of
the anticapsular antibody and MAb B5 in wild-type organisms
(MC58) grown in vitro and in vivo and visualized by confocal
microscopy (Fig. 5). Nor did the presence or absence of sialic
acid have an effect, since both MAb B5-positive and -negative
strains had high sialylation states, as shown by tricine gels (Fig.
6) and confirmed by ES-MS (data not shown).
There was no evidence of phase variation in MAb B5-posi-
tive or -negative strains in this study, except for one strain
(BZ157) which had a very low level of MAb B5-positive strains
in parent and galE mutant (0.06%) (data not shown). Struc-
tural analysis of LPS extracted from these two variants is cur-
rently under investigation.
Three-dimensional space-filling models of the inner core
LPS of L3 and L4 immunotypes show that the position of the
PEtn, either the 3- or the 6-position, respectively (Fig. 3, shown
in brown), alters the accessibility and conformation of PEtn in
the inner core epitope. The most striking example of the im-
portance of PEtn for MAb B5 reactivity was observed when
PEtn was removed from the immunotype L8 (MAb B5 posi-
tive) by treatment with hydrogen fluoride, which totally abol-
ished MAb B5 reactivity.
Previous studies with oligosaccharide conjugates in mice and
rabbits have demonstrated that PEtn is important in immuno-
genicity and in the functional activity of polyclonal antibodies
(67). These studies identified two sets of polyclonal antibodies.
FIG. 6. Silver-stained tricine gels of LPS preparations (10 mg/lane) from N.
meningitidis group B strains which were not reactive with MAb B5. These LPS
preparations were either not treated (2) or treated with neuraminidase (1) to
show the presence of sialic acid. (a) MAb B5-negative strains: lanes 1 and 2,
NGE30; lanes 3 and 4, BZ157; lanes 5 and 6, EG328; lanes 7 and 8, 1000; lanes
9 and 10, 3906. (b) MAb B5-negative strains: lanes 1 and 2, EG327; lanes 3 and
4, NGH38; lanes 5 and 6, NGH15; and MAb B5-positive strain: lanes 7 and 8,
MC58. The presence of sialic acid is indicated (NeuAc). This band was seen in
untreated (2) and removed in treated (1) neuraminidase preparations.
TABLE 4. Negative-ion ES-MS data and proposed compositions of O-deacylated LPS from galE capsule-deficient mutant
N. meningitidis MAb B5-negative strainsa
Strain
Observed ions (m/z) Molecular mass (Da)
Proposed composition
(M-2H)22 (M-H)2 Observed Calculated Lipid Ab
1000 1,213.0 2,427.6 2,427.7 2,427.2 1,075 2Glc, GlcNAc, 2Hep, 2 Kdo, Lipid A
1,252.9 2,507.8 2,507.8 2,507.2 1,155 2Glc, GlcNAc, 2Hep, 2 Kdo, Lipid A
1,314.5 2,630.9 2,630.9 2,630.3 1,278 2Glc, GlcNAc, 2Hep, 2 Kdo, Lipid A
NGH38 1,293.8 2,589.5 2,589.3 2,589.3 952 3Glc, GlcNAc, 2Hep, PEtn, 2Kdo, Lipid A
EG327 1,151.2 2,304.4 2,304.4 2,304.1 952 2Glc, GlcNAc, 2Hep, 2 Kdo, Lipid A
NGE30 1,132.1 2,265.1 1,075 Glc, GlcNAc, 2Hep, 2 Kdo, Lipid A
1,396.1 2,793.4 2,793.7 2,792.5 1,075 3Glc, 2GlcNAc, 2Hep, 2 Kdo, Lipid A
1,436.0 2,873.7 2,873.9 2,872.5 1,155 3Glc, 2GlcNAc, 2Hep, 2 Kdo, Lipid A
1,498.0 2,997.2 2,997.1 2,995.6 1,278 3Glc, 2GlcNAc, 2Hep, 2 Kdo, Lipid A
BZ157 1,274.6 2,551.4 2,550.3 1,075 2Glc, GlcNAc, 2Hep, PEtn, 2Kdo, Lipid A
1,314.8 2,631.1 2,631.2 2,630.3 1,155 2Glc, GlcNAc, 2Hep, PEtn, 2Kdo, Lipid A
1,376.4 2,754.4 2,754.5 2,753.4 1,278 2Glc, GlcNAc, 2Hep, PEtn, 2Kdo, Lipid A
1,457.5 2,916.6 2,916.6 2,915.6 1,278 3Glc, GlcNAc, 2Hep, PEtn, 2Kdo, Lipid A
a Average mass units were used for calculation of molecular weight based on proposed composition as follows: Glc, 162.15; Hep, 192.17; GlcNAc, 203.19; Kdo, 220.18;
PEtn, 123.05. Hep, heptose; Kdo, 3-deoxy-D-manno-octulosonic acid; Glc, glucose; GlcNAc, N-acetylglucosamine; PEtn, phosphoethanolamine.
b As determined by MS-MS analyses.
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One set resulting from L1 and L3,7,9 oligosaccharides had
PEtn in the 3-position of HepII, were immunogenic, and had
opsonophagocytic (OP) activity and chemiluminescence in ox-
idative burst reaction but had no serum bactericidal activity.
The other set of antibodies resulting from L2 conjugates (6- or
7-position or without PEtn at HepII) were poorly immuno-
genic and had greatly reduced OP activity and chemilumines-
cence (67). Future studies will look at the safety and immuno-
genicity of inner core LPS conjugates (PEtn at the 3-position
of HepII and alternative glycoforms) and the functional ability
of these polyclonal antibodies in opsonic and serum bacteri-
cidal assays, initially in mice and rabbits. Preliminary studies
with MAb B5 in an OP assay with N. meningitidis MC58 and
donor human polymorphonuclear cells suggests MAb B5 is
opsonic in the presence of complement and that the uptake of
N. meningitidis bacteria correlates with an oxidative burst re-
action within the neutrophil (data not shown). MAb B5 does
not appear to have any significant serum bactericidal activity
with N. meningitidis MC58; however, this is not unexpected in
view of its isotype (IgG3). The functionality of MAb B5 is
currently under further investigation.
In conclusion, MAb B5 recognizes a conserved inner core
epitope in which the PEtn is at the 3-position of HepII. This
epitope was present in 76% of N. meningitidis group B strains
and in 70% of all N. meningitidis serogroups and was accessible
in the presence of capsule. A limited number of alternative
glycoforms have been identified that are not recognized by
MAb B5 where the PEtn is either absent or at an exocyclic
position of HepII. Therefore, a vaccine containing a limited
number of glycoforms might give 100% coverage of all N.
meningitidis group B strains.
ACKNOWLEDGMENTS
This work was supported by Programme grants from the Medical
Research Council (E.R.M.) and Wellcome Trust (E.R.M. and K.M.).
Funding was also provided by the Oxford Regional Health Authority
Research and Development Programme (J.P. and G.B.), the National
Meningitis Trust (E.R.M. and J.P.), and Chiron vaccines (E.R.M. and
J.R.). M.P.J. was supported by a grant from the NHMRC (96/1084).
We thank D. W. Griffith for large-scale production of bacterial cells,
P. Thibault and D. Krajcarski for recording ES-MS, and J. Eskola for
providing NTHi strains obtained as part of the Finnish Otitis Media
Cohort Study.
REFERENCES
1. Abdillahi, H., and J. T. Poolman. 1988. Typing of group-B Neisseria menin-
gitidis with monoclonal antibodies in the whole-cell ELISA. J. Med. Micro-
biol. 26:177–180.
2. Al’Aldeen, A. A., and K. A. Cartwright. 1996. Neisseria meningitidis: vaccines
and vaccine candidates. J. Infect. 33:153–157.
3. Andersen, S. R., J. Kolberg, E. A. Hoiby, E. Namork, D. A. Caugant, L. O.
Froholm, E. Jantzen, and G. Bjune. 1997. Lipopolysaccharide heterogeneity
and escape mechanisms of Neisseria meningitidis: possible consequences for
vaccine development. Microb. Pathog. 23:139–155.
4. Apicella, M. A., J. M. Griffiss, and H. Schneider. 1994. Isolation and char-
acterization of lipopolysaccharides, lipooligosaccharides, and lipid A. Meth-
ods Enzymol. 235:242–252.
5. Brisson, J. R., S. Uhrinova, R. J. Woods, M. van der Zwan, H. C. Jarrell,
L. C. Paoletti, D. L. Kasper, and H. Jennings. 1997. NMR and molecular
dynamics of the conformational epitope of the type III group B Streptococcus
capsular polysaccharide and derivatives. Biochemistry 36:3278–3292.
6. Buddingh, G. J., and A. Polk. 1937. Meningococcal infection of the chick
embryo. Science 86:20–21.
7. Buddingh, G. J., and A. Polk. 1939. Experimental meningococcal infection of
the chick embryo. J. Exp. Med. 70:485–498.
8. Cadoz, M. 1998. Potential and limitations of polysaccharide vaccines in
infancy. Vaccine 16:1391–1395.
9. Carlin, N. I., M. A. Gidney, A. A. Lindberg, and D. R. Bundle. 1986. Char-
acterization of Shigella flexneri-specific murine monoclonal antibodies by
chemically defined glycoconjugates. J. Immunol. 137:2361–2366.
10. Centers for Disease Control. 1990. Availability of meningococcal vaccine in
single-dose vials for travellers and high-risk persons. Morbid. Mortal.
Weekly Rep. 39:763.
11. Centers for Disease Control. 1997. Communicable disease weekly report,
vol. 7, no. 14. Centers for Disease Control, Atlanta, Ga.
12. DeVoe, I. W. 1982. The meningococcus and mechanisms of pathogenicity.
Microbiol. Rev. 46:162–190.
13. Di Fabio, J. L., F. Michon, J. R. Brisson, and H. J. Jennings. 1990. Structure
of L1 and L6 core oligosaccharide epitopes of Neisseria meningitidis. Can.
J. Chem. 68:1029–1034.
14. Finne, J., M. Leinonen, and P. H. Makela. 1983. Antigenic similarities
between brain components and bacteria causing meningitis. Implications for
vaccine development and pathogenesis. Lancet ii:355–357.
15. Frasch, C. E. 1989. Vaccines for prevention of meningococcal disease. Clin.
Microbiol. Rev. 2(Suppl.):S134–S138.
16. Gamian, A., M. Beurret, F. Michon, J. R. Brisson, and H. J. Jennings. 1992.
Structure of the L2 lipopolysaccharide core oligosaccharides of Neisseria
meningitidis. J. Biol. Chem. 267:922–925.
17. Gotschlich, E. C. 1994. Genetic locus for the biosynthesis of the variable
portion of Neisseria gonorrhoeae lipooligosaccharide. J. Exp. Med. 180:2181–
2190.
18. Griffiss, J. M., J. P. O’Brien, R. Yamensaki, G. D. Williams, P. A. Rice, and
H. Schneider. 1987. Physical heterogenicity of neisserial lipopolysaccharides
reflects oligosaccharides that differ in apparent molecular weight, chemical
composition, and antigenic expression. Infect. Immun. 55:1792–1800.
19. Gu, X. X., and C. M. Tsai. 1993. Preparation, characterization, and immu-
nogenicity of meningococcal lipooligosaccharide-derived oligosaccharide-
protein conjugates. Infect. Immun. 61:1873–1880.
20. Herbert, M. A., P. T. Heath, and R. T. Mayon-White. 1995. Meningococcal
vaccines for the United Kingdom. Commun. Dis. Rep. CDR Rev. 5:R130–
R135.
21. Holten, E. 1979. Serotypes of Neisseria meningitidis isolated from patients in
Norway during the first six months of 1978. J. Clin. Microbiol. 9:186–188.
22. Hood, D. W., M. E. Deadman, T. Allen, H. Masoud, A. Martin, J. R. Brisson,
R. Fleischman, J. C. Venter, J. C. Richards, and E. R. Moxon. 1996. Use of
the complete genome sequence information of Haemophilus influenzae Rd to
investigate lipopolysaccharide biosynthesis. Mol. Microbiol. 22:951–965.
23. Jennings, H. J. 1989. The capsular polysaccharide of group B Neisseria
meningitidis as a vehicle for vaccine development. Contrib. Microbiol. Im-
munol. 10:151–165.
24. Jennings, H. J., and H. C. Lugowsji. 1981. Immunochemistry of groups A, B,
and C meningococcal polysaccharide-tetanus toxoid conjugates. J. Immunol.
127:1011–1018.
25. Jennings, H. J., C. Lugowski, and F. E. Ashton. 1984. Conjugation of me-
ningococcal lipopolysaccharide R-type oligosaccharides to tetanus toxoid as
route to a potential vaccine against group B Neisseria meningitidis. Infect.
Immun. 43:407–412.
26. Jennings, H. J., K. J. Johnson, and L. Kenne. 1983. The structure of an
R-type oligosaccharide core obtained from some lipopolysaccharides of
Neisseria meningitidis. Carbohydr. Res. 121:233–241.
27. Jennings, H. J., M. Beurret, A. Gamian, and F. Michon. 1987. Structure and
immunochemistry of meningococcal lipopolysaccharides. Antonie Leeuwen-
hoek 53:519–522.
28. Jennings, M. P., D. W. Hood, I. R. Peak, M. Virji, and E. R. Moxon. 1995.
Molecular analysis of a locus for the biosynthesis and phase-variable expres-
sion of the lacto-N-neotetraose terminal lipopolysaccharide structure in
Neisseria meningitidis. Mol. Microbiol. 18:729–740.
29. Jennings, M. P., M. Bisercic, K. L. Dunn, M. Virji, A. Martin, K. E. Wilks,
J. C. Richards, and E. R. Moxon. 1995. Cloning and molecular analysis of the
lsi1 (rfaF) gene of Neisseria meningitidis which encodes a heptosyl-2-trans-
ferase involved in LPS biosynthesis: evaluation of surface exposed carbohy-
drates in LPS mediated toxicity for human endothelial cells. Microb. Pathog.
19:391–407.
30. Jennings, M. P., P. van der Ley, K. E. Wilks, D. J. Maskell, J. T. Poolman,
and E. R. Moxon. 1993. Cloning and molecular analysis of the galE gene of
Neisseria meningitidis and its role in lipopolysaccharide biosynthesis. Mol.
Microbiol. 10:361–369.
31. Jonsson, A. B., G. Nyberg, and S. Normark. 1991. Phase variation of gono-
coccal pili by frameshift mutation in pilC, a novel gene for pilus assembly.
EMBO J. 10:477–488.
32. Kogan, G., D. Uhrin, J. R. Brisson, and H. J. Jennings. 1997. Structural basis
of the Neisseria meningitidis immunotypes, including the L4 and L7 immu-
notypes. Carbohydr. Res. 298:191–199.
33. Lepow, M. L., J. Beeler, M. Randolph, J. S. Samuelson, and W. A. Hankins.
1986. Reactogenicity and immunogenicity of a quadrivalent combined me-
ningococcal polysaccharide vaccine in children. J. Infect. Dis. 154:1033–1036.
34. Lesse, A. J., A. A. Campagnari, W. E. Bittner, and M. A. Apicella. 1990.
Increased resolution of lipopolysaccharides and lipopoligosaccharides utiliz-
ing tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis. J. Im-
munol. Methods 126:109–117.
35. Maiden, M. C. J., J. A. Bygraves, E. Feil, G. Morelli, J. E. Russell, R. Urwin,
Q. Zhang, J. Zhou, K. Zurth, D. A. Caugant, I. M. Feavers, M. Achtman, and
B. G. Spratt. 1998. Multilocus sequence typing: a portable approach to the
identification of clones within populations of pathogenic microorganisms.
Proc. Natl. Acad. Sci. USA 95:3140–3145.
VOL. 67, 1999 MENINGOCOCCAL INNER CORE LPS EPITOPE 5425
 o
n
 O
ctober 13, 2015 by University of Queensland Library
http://iai.asm
.org/
D
ow
nloaded from
 
36. Masoud, H., E. R. Moxon, A. Martin, D. Krajcarski, and J. C. Richards.
1997. Structure of the variable and conserved lipopolysaccharide oligosac-
charide epitopes expressed by Haemophilus influenzae serotype b Eagan.
Biochemistry 36:2091–2103.
37. Michon, F., M. Beurret, A. Gamian, J. R. Brisson, and H. J. Jennings. 1990.
Structure of the L5 lipopolysaccharide core oligosaccharide of Neisseria
meningitidis. J. Biol. Chem. 265:7243–7247.
38. Moxon, E. R., D. Hood, and J. C. Richards. 1998. Bacterial lipopolysaccha-
rides: candidate vaccines to prevent Neisseria meningitidis and Haemophilus
influenzae infections. Adv. Exp. Med. Biol. 435:237–243.
39. Nassif, X., M. Marceau, C. Pujol, B. Pron, J. L. Beretti, and M. K. Taha.
1997. Type-4 pili and meningococcal adhesiveness. Gene 192:149–153.
40. Neidhardt, F. C. 1996. Derivations and genotypes of some mutant derivatives
of Escherichia coli K-12, p. 2460–2488. In F. C. Neidhardt, R. Curtiss III, J. L.
Ingraham, E. C. C. Lin, K. Low, Jr., B. Magasanik, W. S. Reznikoff, M. Riley,
M. Schaechter, and H. E. Umbarger (ed.), Escherichia coli and Salmonella,
2nd ed. ASM Press, Washington, D.C.
41. Pavliak, V., J. R. Brisson, F. Michon, D. Uhrin, and H. J. Jennings. 1993.
Structure of the sialylated L3 lipopolysaccharide of Neisseria meningitidis.
J. Biol. Chem. 268:14146–14152.
42. Peltola, H., A. Safary, H. Kayhty, V. Karanko, and F. E. Andre. 1985.
Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants
and small children: a clinical study comparing immunogenicity of O-acetyl-
negative and O-acetyl-positive group C polysaccharides. Pediatrics 76:91–96.
43. Peltola, H., H. Makela, H. Kayhty, H. Jousimies, E. Herva, K. Hallstrom, A.
Sivonen, O. V. Renkonen, O. Pettay, V. Karanko, P. Ahvonen, and S. Sarna.
1977. Clinical efficacy of meningococcus group A capsular polysaccharide
vaccine in children three months to five years of age. N. Engl. J. Med.
297:686–691.
44. Poolman, J. T. 1990. Polysaccharides and membrane vaccines, p. 57–86. In A.
Mizrahi (ed.), Bacterial vaccines. Wiley-Liss, New York, N.Y.
45. Poolman, J. T. 1996. Bacterial outer membrane protein vaccines. The me-
ningococcal example. Adv. Exp. Med. Biol. 397:73–77.
46. Poolman, J. T., C. T. P. Hopman, and H. C. Zanen. 1982. Problems in the
definition of meningococcal serotypes. FEMS Microbiol. Lett. 13:339–348.
47. Poolman, J. T., P. van der Ley, and J. P. M. Tommassen. 1995. Surface
structures and secreted products of meningococci, p. 21–34. K. Cartwright
(ed.), Meningococcal disease. John Wiley & Sons, Inc., New York, N.Y.
48. Preston, A., R. E. Mandrell, B. W. Gibson, and M. A. Apicella. 1996. The
lipooligosaccharides of pathogenic gram-negative bacteria. Crit. Rev. Micro-
biol. 22:139–180.
49. Reingold, A. L., C. V. Broome, G. W. Hightower, G. A. Ajello, C. Bolaw, E. E.
Adambauw, C. Jones, H. Phillips, H. Tiendrebeogo, and A. Yada. 1985.
Age-specific differences in duration of clinical protection after vaccination
with polysaccharide A vaccine. Lancet ii:114–118.
50. Rosenqvist, E., E. A. Hoiby, E. Wedege, K. Bryn, J. Kolberg, A. Klem, E.
Ronnild, G. Bjune, and H. Nokleby. 1995. Human antibody responses to
meningococcal outer membrane antigens after three doses of the Norwegian
group B meningococcal vaccine. Infect. Immun. 63:4642–4652.
51. Rosenstein, N., O. Levine, J. P. Taylor, D. Evans, B. D. Plikaytis, J. D.
Wenger, and B. A. Perkins. 1998. Efficacy of meningococcal vaccine and
barriers to vaccination. JAMA 279:435–439.
52. Sakari, J., N. Pandit, E. R. Moxon, and M. Achtman. 1994. Variable expres-
sion of the Opc outer membrane protein in Neisseria meningitidis is caused by
size variation of a promoter containing poly-cytidine. Mol. Microbiol. 13:
207–217.
53. Schnaitman, C. A., and F. D. Klena. 1993. Genetics of lipopolysaccharide
biosynthesis in enteric bacteria. Microbiol. Rev. 57:655–682.
54. Scholten, R. J., B. Kuipers, H. A. Valkenburg, J. Dankert, W. D. Zollinger,
and J. T. Poolman. 1994. Lipo-oligosaccharide immunotyping of Neisseria
meningitidis by a whole-cell ELISA with monoclonal antibodies. J. Med.
Microbiol. 41:236–243.
55. Schroten, H., M. Deadman, and E. R. Moxon. 1995. Development of chick
embryo models for analysis of bacterial virulence factors. Pediatr. Grenzgeb.
34:319–324.
56. Seiler, A., R. Reinhardt, J. Sakari, D. A. Caugant, and M. Achtman. 1996.
Allelic polymorphisms and site-specific recombination in the opc locus of
Neisseria meningitidis. Mol. Microbiol. 19:841–856.
57. Shulman, M., C. D. Wilde, and G. Kohler. 1978. A better cell line for making
hybridomas secreting specific antibodies. Nature 276:269–270.
58. Steeghs, L., R. den Hartog, A. den Boer, B. Zomer, P. Roholl, and P. van der
Ley. 1998. Meningitis bacterium is viable without endotoxin. Nature 392:
449–450.
59. Stephens, D. S., C. F. McAllister, D. Zhou, F. K. Lee, and M. A. Apicella.
1994. Tn916-generated, lipooligosaccharide mutants of Neisseria meningitidis
and Neisseria gonorrhoeae. Infect. Immun. 62:2947–2952.
60. Stern, A., and T. F. Meyer. 1987. Common mechanism controlling phase and
antigenic variation in pathogenic neisseriae. Mol. Microbiol. 1:5–12.
61. Stern, A., M. Brown, P. Nickel, and T. F. Meyer. 1986. Opacity genes in
Neisseria gonorrhoea: control of phase and antigenic variation. Cell 47:61–71.
62. Stoiljkovic, I., V. Hwa, J. Larson, L. Lin, M. So, and X. Nassif. 1997. Cloning
and characterization of the Neisseria meningitidis rfaC gene encoding alpha-
1,5-heptosyltransferase I. FEMS Microbiol. Lett. 151:41–49.
63. Tonjum, T., and M. Koomey. 1997. The pilus colonization factor of patho-
genic neisserial species: organelle biosynthesis and structure/function rela-
tionships—a review. Gene 192:155–163.
64. van der Ley, P., M. Kramer, A. Martin, J. C. Richards, and J. T. Poolman.
1997. Analysis of the icsBA locus required for biosynthesis of the inner core
region from Neisseria meningitidis lipopolysaccharide. FEMS Microbiol. Lett.
146:247–253.
65. van der Ley, P., M. Kramer, L. Steeghs, B. Kuipers, S. R. Andersen, M. P.
Jennings, E. R. Moxon, and J. T. Poolman. 1996. Identification of a locus
involved in meningococcal lipopolysaccharide biosynthesis by deletion mu-
tagenesis. Mol. Microbiol. 19:1117–1125.
66. van Putten, J. P., and B. D. Robertson. 1995. Molecular mechanisms and
implications for infection of lipopolysaccharide variation in Neisseria. Mol.
Microbiol. 16:847–853.
67. Verheul, A. F., A. K. Braat, J. M. Leenhouts, P. Hoogerhout, J. T. Poolman,
H. Snippe, and J. Verhoef. 1991. Preparation, characterization, and immu-
nogenicity of meningococcal immunotype L2 and L3,7,9 phosphoethano-
lamine group-containing oligosaccharide-protein conjugates. Infect. Immun.
59:843–851.
68. Verheul, A. F., H. Snippe, and J. T. Poolman. 1993. Meningococcal lipopoly-
saccharides: virulence factor and potential vaccine component. Microbiol.
Rev. 57:34–49.
69. Verheul, A. F., J. A. Van Gaans, E. J. Wiertz, H. Snippe, J. Verhoef, and J. T.
Poolman. 1993. Meningococcal lipopolysaccharide (LPS)-derived oligosac-
charide-protein conjugates evoke outer membrane protein- but not LPS-
specific bactericidal antibodies in mice: influence of adjuvants. Infect. Im-
mun. 61:187–196.
70. Virji, M., H. Kayhty, D. J. P. Ferguson, C. Alexandrescu, J. E. Heckels, and
E. R. Moxon. 1991. Interactions of Haemophilus influenzae with cultured
human endothelial cells. Microb. Pathog. 10:231–245.
71. Virji, M., H. Kayhty, D. J. P. Ferguson, J. E. Heckels, and E. R. Moxon. 1991.
The role of pili in the interactions of pathogenic Neisseria with cultured
human endothelial cells. Mol. Microbiol. 5:1831–1841.
72. Wakarchuk, W., A. Martin, M. P. Jennings, E. R. Moxon, and J. C. Richards.
1996. Functional relationships of the genetic locus encoding the glycosyl-
transferase enzymes involved in expression of the lacto-N-neotetraose ter-
minal lipopolysaccharide structure in Neisseria meningitidis. J. Biol. Chem.
271:19166–19173.
73. Wakarchuk, W. W., M. Gilbert, A. Martin, Y. Wu, J. R. Brisson, P. Thibault,
and J. C. Richards. 1998. Structure of an alpha-2,6-sialylated lipooligosac-
charide from Neisseria meningitidis immunotype L1. Eur. J. Biochem. 254:
626–633.
74. Westphal, O., and J. K. Jann. 1965. Bacterial lipopolysaccharides extraction
with water-phenol and further applications of the procedure. Methods Car-
bohydr. Chem. 5:83–91.
75. Wetzler, L. M. 1994. Immunopotentiating ability of neisserial major outer
membrane proteins. Use as an adjuvant for poorly immunogenic substances
and potential use in vaccines. Ann. N. Y. Acad. Sci. 730:367–370.
76. Zollinger, W. D., E. E. Moran, S. J. Devi, and C. E. Frasch. 1997. Bacteri-
cidal antibody responses of juvenile rhesus monkeys immunized with group
B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines.
Infect. Immun. 65:1053–1060.
Editor: T. R. Kozel
5426 PLESTED ET AL. INFECT. IMMUN.
 o
n
 O
ctober 13, 2015 by University of Queensland Library
http://iai.asm
.org/
D
ow
nloaded from
 
